Brain Cancer Research Core (BCRC), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran.
Fundam Clin Pharmacol. 2022 Feb;36(1):35-48. doi: 10.1111/fcp.12712. Epub 2021 Jul 29.
Glioblastoma multiforme (GBM) is known as the deadliest form of brain tumor. In addition, its high treatment resistance, heterogeneity, and invasiveness make it one of the most challenging tumors. Depression is a common psychological disorder among patients with cancer, especially GBM. Due to the high occurrence rates of depression in GBM patients and the overlap of molecular and cellular mechanisms involved in the pathogenesis of these diseases, finding antidepressants with antitumor effects could be considered as an affordable strategy for the treatment of GBM. Antidepressants exert their antitumor properties through different mechanisms. According to available evidence in this regard, some of them can eliminate the adverse effects resulting from chemo-radiotherapy in several cancers along with their synergistic effects caused by chemotherapy. Therefore, providing comprehensive insight into this issue would guide scientists and physicians in developing further preclinical studies and clinical trials, in order to evaluate antidepressants' antitumor potential. Considering that no narrative review has been recently published on this issue, specifically on these classes of drugs, we present this article with the purpose of describing the antitumor cellular mechanisms of three classes of antidepressants as follows: tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAOIs) in GBM.
多形性胶质母细胞瘤（GBM）是最致命的脑肿瘤之一。此外，其高治疗抗性、异质性和侵袭性使其成为最具挑战性的肿瘤之一。抑郁症是癌症患者中常见的心理障碍，尤其是 GBM。由于 GBM 患者中抑郁症的高发生率以及这些疾病发病机制中涉及的分子和细胞机制的重叠，寻找具有抗肿瘤作用的抗抑郁药可能被认为是治疗 GBM 的一种经济实惠的策略。抗抑郁药通过不同的机制发挥其抗肿瘤特性。根据这方面的现有证据，其中一些药物可以消除几种癌症化疗和放疗的不良影响，以及它们与化疗的协同作用。因此，全面了解这一问题将指导科学家和医生进行进一步的临床前研究和临床试验，以评估抗抑郁药的抗肿瘤潜力。鉴于最近没有关于这个问题的叙述性综述，特别是关于这些类别的药物，我们撰写了这篇文章，目的是描述三环类抗抑郁药（TCAs）、选择性 5-羟色胺再摄取抑制剂（SSRIs）和单胺氧化酶抑制剂（MAOIs）在 GBM 中的抗肿瘤细胞机制。
